| All Releases |
|---|
 |
Notice of Time Change for Alexion's Presentation at the Bank of America 2008 Health Care Conference
May 9, 2008
|
7.2 KB
|
| |
CHESHIRE, Conn., May 9, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the time of Alexion's presentation at the Bank of America 2008 Health Care Conference in Las Vegas has been changed to 4:00 p.m., local time (7:00 p.m., eastern) on Tuesday, May 13, 2008. Vikas Sinha, Seni...
|
|
|
Alexion to Present at the Bank of America 2008 Health Care Conference
May 6, 2008
|
7.1 KB
|
| |
CHESHIRE, Conn., May 6, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Vikas Sinha, Senior Vice President and Chief Financial Officer of Alexion Pharmaceuticals, will present at the Bank of America 2008 Health Care Conference in Las Vegas at 4:40 p.m., local time (7:40 p.m., ...
|
|
|
Alexion Reports First Quarter 2008 Results
Apr 30, 2008
|
21.8 KB
|
| |
CHESHIRE, Conn., April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Growing Awareness of PNH Drives Strong Demand for Soliris(R) in U.S. and
Europe
First Non-GAAP Profit; Sales Guidance Revised Upward
Pipeline Progress in Neurology and Cancer
First Qua...
|
|
|
Alexion to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Apr 24, 2008
|
7.1 KB
|
| |
CHESHIRE, Conn., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Morgan Stanley Global Healthcare Unplugged Conference in Key Biscayne, Florida at 5:00 p.m. ET on Thursday, May ...
|
|
|
Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
Apr 14, 2008
|
7.3 KB
|
| |
CHESHIRE, Conn., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the Company will conduct a conference call and audio web cast on Wednesday, April 30, 2008, at 10:00 a.m. Eastern Time (ET), in conjunction with the release of its financial results for the first quart...
|
|
|
Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
Mar 20, 2008
|
15.2 KB
|
| |
CHESHIRE, Conn., March 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (the "Company") (Nasdaq: ALXN) today announced that it has completed enrolling patients in its previously announced AEGIS study, a single registration study to evaluate the safety, efficacy, and pharmacology of Soliris(R) (eculizumab) as ...
|
|
|
Alexion to Present at Investor Conferences
Mar 11, 2008
|
7.2 KB
|
| |
CHESHIRE, Conn., March 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Leonard Bell, M.D., Chief Executive Officer of Alexion Pharmaceuticals, will present at two upcoming investor conferences, one sponsored by Cowen and Company and the other by Lehman Brothers.
Dr. Be...
|
|
|
Alexion Reports Fourth Quarter and Full Year 2007 Results
Feb 14, 2008
|
23.7 KB
|
| |
CHESHIRE, Conn., Feb 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Soliris(R) Sales Reflect Strong 2007 Launch; Positioned for Expanded Growth in
U.S. and International Markets
Fourth Quarter and 2007 Financial Highlights:
* Soliris(R) (eculizumab) net product sales were $33.9 million in Q4 20...
|
|
|
Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
Feb 14, 2008
|
10.5 KB
|
| |
CHESHIRE, Conn., Feb 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- The Oklahoma Medical Research Foundation ("OMRF") and Alexion Pharmaceuticals, Inc. ("Alexion," Nasdaq: ALXN) today announced that Alexion has agreed to acquire from OMRF all rights to certain patents related to complement-inhibition technology.
Background
The p...
|
|
|
Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
Jan 28, 2008
|
7.3 KB
|
| |
CHESHIRE, Conn., Jan 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that the Company will conduct a conference call and audio web cast on Thursday, February 14, 2008, at 10:00 a.m. Eastern Time (ET), in conjunction with the release of its financial results for the fourth quar...
|
|
|
Alexion to Present at the Wachovia Securities 2008 Healthcare Conference
Jan 24, 2008
|
7.1 KB
|
| |
CHESHIRE, Conn., Jan 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Wachovia Securities 2008 Healthcare Conference in Boston at 9:00 a.m. ET on Thursday, January 31, 2008.
An aud...
|
|
|
Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
Jan 7, 2008
|
15.7 KB
|
| |
CHESHIRE, Conn., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (the "Company," Nasdaq: ALXN) today announced that it has commenced dosing in the AEGIS study, a single registration study to evaluate the safety, efficacy, and pharmacology of Soliris(R) (eculizumab) as a treatment for Japanese patients wi...
|
|
|
Alexion to Present at the 26th Annual JP Morgan Healthcare Conference
Jan 2, 2008
|
7.1 KB
|
| |
CHESHIRE, Conn., Jan 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the 26th Annual JP Morgan Healthcare Conference in San Francisco at 4:00 p.m. local time (7:00 p.m. Eastern) on Monday...
|
|
|
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Dec 11, 2007
|
18.1 KB
|
| |
CHESHIRE, Conn., Dec 11, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Soliris(R) (eculizumab) therapy reduced hemolysis, fatigue, thromboses (blood clots) and transfusion requirements in patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), including those who might have been expected to have less severe di...
|
|
|
Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH
Dec 10, 2007
|
20.3 KB
|
| |
CHESHIRE, Conn., Dec 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH) were found to be six times more likely than the general public to have chronic kidney disease (CKD), as shown in an ongoing open-label clinical study of patients with PNH. Additionally,...
|
|
|
Alexion Pharmaceuticals to Present Data on Soliris® (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting
Dec 7, 2007
|
7.5 KB
|
| |
CHESHIRE, Conn., Dec 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris® (eculizumab), a treatment for patients with PNH, will be presented at the 2007 Amer...
|
|
|
Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
Dec 4, 2007
|
17.1 KB
|
| |
CHESHIRE, Conn., Dec 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Soliris(R) (eculizumab) therapy reduced hemolysis and improved fatigue, overall quality of life and anemia in a diverse population of patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), according to an analysis of the Phase III SHEPHERD...
|
|
|
Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting
Nov 9, 2007
|
8.5 KB
|
| |
CHESHIRE, Conn., Nov 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab) as a treatment for patients with PNH, have been published by the American Society of Hematology (ASH). Abs...
|
|
|
Alexion to Present at Investor Conferences
Nov 6, 2007
|
7.2 KB
|
| |
CHESHIRE, Conn., Nov 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Leonard Bell, M.D., Chief Executive Officer of Alexion Pharmaceuticals, will present at two upcoming investor conferences, one sponsored by Citigroup Global Markets, Inc. and the other by Credit Suisse.
...
|
|
|
Alexion Reports Third Quarter 2007 Results
Oct 25, 2007
|
19.6 KB
|
| |
CHESHIRE, Conn., Oct 25, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the quarter ended September 30, 2007.
Third Quarter 2007 Financial Results:
For the three months ended September 30, 2007, Alexion Pharmaceuticals, Inc. (the "Company" or "Alexion...
|
|
|
